This content is from: Home

Bayer fights India’s compulsory licence ruling

German pharmaceutical company Bayer has appealed a decision by India’s Controller of Patents to grant a compulsory license over its cancer treatment drug sorafenib

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | One Week Trial